Filtered By:
Specialty: Endocrinology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 648 results found since Jan 2013.

Systemic Delivery of siRNA Specific for Silencing TLR4 Gene Expression Reduces Diabetic Cardiomyopathy in a Mouse Model of Streptozotocin-Induced Type  1 Diabetes
ConclusionOur study used siRNA to specifically silence TLR4 gene expression in the diabetic mouse heart in vivo and to investigate the role that TLR4 plays in diabetic cardiomyopathy. It is likely that silencing of the TLR4 gene through siRNA could prevent the development of diabetic cardiomyopathy.
Source: Diabetes Therapy - April 12, 2020 Category: Endocrinology Source Type: research

Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function in vitro; however, limitations were associated with its utility in vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple-negative breast cancer (TNBC). TNBC is...
Source: Endocrine-Related Cancer - March 9, 2017 Category: Endocrinology Authors: Parvani, J. G., Jackson, M. W. Tags: Review Source Type: research

Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes
Conclusion While leptin may be more effective than Gcgr siRNA at normalizing both glucose and lipid metabolism in STZ diabetes, Gcgr siRNA is more effective at reducing blood glucose levels in HFD/STZ diabetes.
Source: Molecular Metabolism - June 23, 2017 Category: Endocrinology Source Type: research

Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease
Conclusions These preliminary data suggest that both the biologically active ICAM-1 mAb and the siRNA targeting TSHR were effective. The ICAM-1 mAb exerted a better therapeutic effect than the siRNA targeting TSHR. Both treatments showed potential efficacy as novel treatments for GD and may therefore represent therapeutic options in addition to the existing drugs or interventions.PMID:34647608 | DOI:10.5603/EP.a2021.0087
Source: Endokrynologia Polska - October 14, 2021 Category: Endocrinology Authors: Xuan Wang Wei Liu Zhongying Rui Wei Zheng Jian Tan Ning Li Yang Yu Source Type: research